Trading Signals: ABBV Stock Price Prediction and Forecast (Mon. Mar. 17, 2014 - Fri. Dec. 22, 2023)(AbbVie Inc.)
| ABBV latest price $91.0730 (1.17%) ($90.1247 - $91.8633) on Mon. Dec. 31, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.17% (three month average) | RSI | 61 | Latest Price | $91.0730(1.17%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ABBV advances 1.7% a day on average for past five trading days. | Weekly Trend | ABBV advances 1.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ABBV advance at 0% a week (0% probability) XLV(60%) VYM(50%) IVE(49%) SPLV(49%) IWD(48%) | Factors Impacting ABBV price | ABBV will decline at least -1.085% in a week (0% probabilities). TLT(-15%) DIA(-14%) VXX(-12%) VIXM(-11%) UUP(-11%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.085% (StdDev 2.17%) | Hourly BBV | 0 () | Intraday Trend | 0.6% | | | |
|
5 Day Moving Average | $88.2(3.26%) | 10 Day Moving Average | $86(5.9%) | 20 Day Moving Average | $86.98(4.71%) | To recent high | -3% | To recent low | 18.4% | Market Cap | $160.679b | | | | AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. |